RVNC: Rega marang dodolan Revance Therapeutics Inc

Revance Therapeutics (RVNC) has established a closed B2B ecosystem around Daxxify, securing clinics through exclusive supply agreements. The current P/S multiple reflects the market valuation of sales, where the 1.50 mark indicates the business value level. The company generates revenue through the sale of fillers and botulinum toxins. Growth prospects are based on the expansion of the drugs' therapeutic properties and successful clinical trials.

Revance Therapeutics (RVNC) maintains production independence through its own automated plant in California, which allows investors to track the monetization efficiency of these manufacturing capacities via P/S ratio history. This multiple compares market capitalization to annual revenue, determining the cost of each unit of sales and helping investors distinguish fundamental business growth from speculative asset price overheating.